首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL18 |
| Uniprot No | Q14116 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-193aa |
| 氨基酸序列 | MYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFII SMYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDI IFFQRSVPGHDNKMQFESSSYEGYFLACEKERDLFKLILKKEDELGDRSI MFTVQNED |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-18重组蛋白的3篇参考文献的简要总结：
---
1. **标题**：*"IL-18: A key cytokine in autoimmune and inflammatory diseases"*
**作者**：Dinarello, C.A. et al.
**摘要**：探讨IL-18重组蛋白在炎症反应和自身免疫疾病中的调控作用，揭示其通过激活NF-κB通路促进干扰素γ(IFN-γ)分泌的机制，并讨论其作为治疗靶点的潜力。
2. **标题**：*"Recombinant IL-18 enhances anti-tumor immunity through NK cell activation"*
**作者**：Smyth, M.J. et al.
**摘要**：研究重组IL-18蛋白在小鼠肿瘤模型中的免疫调节功能，证明其通过激活自然杀伤(NK)细胞和增强CD8+ T细胞应答，显著抑制肿瘤生长，提出联合免疫治疗的策略。
3. **标题**：*"IL-18 binding protein fusion construct ameliorates colitis in murine models"*
**作者**：Kim, S.H. et al.
**摘要**：开发重组IL-18结合蛋白(IL-18BP)融合分子，验证其通过中和IL-18的促炎作用缓解实验性结肠炎的效果，为治疗炎症性肠病(IBD)提供新思路。
---
以上文献涵盖IL-18重组蛋白的机制研究、抗肿瘤应用及炎症疾病治疗，均为该领域的代表性工作。
**Background of IL-18 Recombinant Protein**
Interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the interleukin-1 (IL-1) superfamily, plays a pivotal role in regulating innate and adaptive immune responses. Initially identified as an interferon-gamma (IFN-γ)-inducing factor, IL-18 is synthesized as an inactive precursor (pro-IL-18) that requires proteolytic cleavage by caspase-1 or other proteases to become biologically active. It signals through a heterodimeric receptor complex comprising IL-18Rα and IL-18Rβ, activating downstream pathways like NF-κB and MAPK to modulate immune cell functions, including T-cell differentiation, macrophage activation, and NK cell cytotoxicity.
Recombinant IL-18 protein is produced via genetic engineering, typically using *E. coli*, mammalian cells, or yeast expression systems. This technology enables large-scale production of highly pure, bioactive IL-18 for research and therapeutic applications. Studies highlight its dual role in immunity: it promotes anti-tumor and anti-pathogen responses by enhancing IFN-γ production but can also exacerbate inflammatory diseases (e.g., rheumatoid arthritis, sepsis) when dysregulated.
In preclinical research, recombinant IL-18 has shown potential in cancer immunotherapy, either as a standalone agent or in combination with checkpoint inhibitors. Conversely, IL-18 inhibition via neutralizing antibodies or decoy receptors is being explored to treat autoimmune disorders. Challenges remain in understanding its context-dependent effects and optimizing delivery strategies to minimize toxicity.
Overall, IL-18 recombinant protein serves as a critical tool for dissecting immune pathways and developing targeted therapies, though its clinical translation requires careful balancing of its pro-inflammatory and therapeutic benefits.
×
